nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.02.2016 | Original Article

Characterization of endocrine features and genotype–phenotypes correlations in blepharophimosis–ptosis–epicanthus inversus syndrome type 1

verfasst von: S. Nuovo, M. Passeri, E. Di Benedetto, M. Calanchini, I. Meldolesi, M. C. Di Giacomo, D. Petruzzi, M. R. Piemontese, L. Zelante, F. Sangiuolo, G. Novelli, A. Fabbri, F. Brancati

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Blepharophimosis syndrome (BPES) is an autosomal dominant genetic condition resulting from heterozygous mutations in the FOXL2 gene and clinically characterized by an eyelid malformation associated (type I) or not (type II) with premature ovarian failure. The distinction between the two forms is critical for female patients, as it may allow to predict fertility and to plan an appropriate therapy. Identifying an underlying causative mutation is not always predictive of the clinical type of BPES since genotype–phenotype correlations are not yet fully delineated. Here, we describe the clinical and hormonal phenotypes of three female patients with BPES type 1 from two novel families, correlate their phenotypes with identified mutations, and investigate the effects of hormone replacement therapy (HRT).

Methods

Clinical, biochemical, and genetic evaluation were undertaken in all the patients and genotype–phenotype correlation was analyzed. The effects of substitutive hormonal therapy on secondary sexual characteristics development and induction of menarche were evaluated.

Results

All patients presented with primary amenorrhea or other signs of ovarian dysfunction. Two distinct mutations, a missense p.H104R change and an in-frame p.A222_A231dup10 duplication in the FOXL2 gene were identified. Observed phenotypes were not in accordance with the prediction based on the current genotype–phenotype correlations. HRT significantly improved secondary sexual characteristics development, as well as the induction of menarche.

Conclusions

This study highlights the importance of early recognition of BPES and emphasizes the need of personalized therapy and follow-up in female patients carrying distinct FOXL2 mutations.

Zlotogora J, Sagi M, Cohen T (1983) The blepharophimosis, ptosis, and epicanthus inversus syndrome: delineation of two types. Am J Hum Genet 35:1020–1027PubMedPubMedCentral

Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, Ristaldi MS, Marzella R, Rocchi M, Nicolino M, Lienhardt-Roussie A, Nivelon A, Verloes A, Schlessinger D, Gasparini P, Bonneau D, Cao A, Pilia G (2001) The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27:159–166PubMedCrossRef

Cocquet J, Pailhoux E, Jaubert F, Servel N, Xia X, Pannetier M, De Baere E, Messiaen L, Cotinot C, Fellous M, Veitia RA (2002) Evolution and expression of FOXL2. J Med Genet 39:916–921PubMedPubMedCentralCrossRef

Cocquet J, De Baere E, Gareil M, Pannetier M, Xia X, Fellous M, Veitia RA (2003) Structure, evolution and expression of the FOXL2 transcription unit. Cytogenet Genome Res 101:206–211PubMedCrossRef

Ellsworth BS, Egashira N, Haller JL, Butts DL, Cocquet J, Clay CM, Osamura RY, Camper SA (2006) FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol 20:2796–2805PubMedCrossRef

De Baere E, Beysen D, Oley C, Lorenz B, Cocquet J, De Sutter P, Devriendt K, Dixon M, Fellous M, Fryns JP, Garza A, Jonsrud C, Koivisto PA, Krause A, Leroy BP, Meire F, Plomp A, Van Maldergem L, De Paepe A, Veitia R, Messiaen L (2003) FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet 72:478–487PubMedPubMedCentralCrossRef

Fokstuen S, Antonarakis SE, Blouin JL (2003) FOXL2-mutations in blepharophimosis-ptosis-epicanthus inversus syndrome (BPES); challenges for genetic counseling in female patients. Am J Med Genet A 117A:143–146PubMedCrossRef

Udar N, Yellore V, Chalukya M, Yelchits S, Silva-Garcia R, Small K (2003) Comparative analysis of the FOXL2 gene and characterization of mutations in BPES patients. Hum Mutat 22:222–228PubMedCrossRef

Fraser IS, Shearman RP, Smith A, Russell P (1988) An association among blepharophimosis, resistant ovary syndrome, and true premature menopause. Fertil Steril 50:747–751PubMed

10.

Raile K, Stobbe H, Tröbs RB, Kiess W, Pfäffle R (2005) A new heterozygous mutation of the FOXL2 gene is associated with a large ovarian cyst and ovarian dysfunction in an adolescent girl with blepharophimosis/ptosis/epicanthus inversus syndrome. Eur J Endocrinol 153:353–358PubMedCrossRef

11.

Méduri G, Bachelot A, Duflos C, Bständig B, Poirot C, Genestie C, Veitia R, De Baere E, Touraine P (2010) FOXL2 mutations lead to different ovarian phenotypes in BPES patients: case report. Hum Reprod 25:235–243PubMedCrossRef

12.

Amati P, Gasparini P, Zlotogora J, Zelante L, Chomel JC, Kitzis A, Kaplan J, Bonneau D (1996) A gene for premature ovarian failure associated with eyelid malformation maps to chromosome 3q22-q23. Am J Hum Genet 58:1089–1092PubMedPubMedCentral

13.

Beysen D, Moumné L, Veitia R, Peters H, Leroy BP, De Paepe A, De Baere E (2008) Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation. Hum Mol Genet 17:2030–2038PubMedCrossRef

14.

Dipietromaria A, Benayoun BA, Todeschini AL, Rivals I, Bazin C, Veitia RA (2009) Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. Hum Mol Genet 18:3324–3333PubMedCrossRef

15.

Todeschini AL, Dipietromaria A, L’Hôte D, Boucham FZ, Georges AB, Pandaranayaka PJE, Krishnaswamy S, Rivals I, Bazin C, Veitia RA (2011) Mutational probing of the forkhead domain of the transcription factor FOXL2 provides insights into the pathogenicity of naturally occurring mutations. Hum Mol Genet 20:3376–3385PubMedCrossRef

16.

De Baere E, Dixon MJ, Small KW, Jabs EW, Leroy BP, Devriendt K, Gillerot Y, Mortier G, Meire F, Van Maldergem L, Courtens W, Hjalgrim H, Huang S, Liebaers I, Van Regemorter N, Touraine P, Praphanphoj V, Verloes A, Udar N, Yellore V, Chalukya M, Yelchits S, De Paepe A, Kuttenn F, Fellous M, Veitia R, Messiaen L (2001) Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype–phenotype correlation. Hum Mol Genet 10:1591–1600PubMedCrossRef

17.

Nallathambi J, Moumné L, De Baere E, Beysen D, Usha K, Sundaresan P, Veitia RA (2007) A novel polyalanine expansion in FOXL2: the first evidence for a recessive form of the blepharophimosis syndrome (BPES) associated with ovarian dysfunction. Hum Genet 121:107–112PubMedCrossRef

18.

Beysen D, De Jaegere S, Amor D, Bouchard P, Christin-Maitre S, Fellous M, Touraine P, Grix AW, Hennekam R, Meire F, Oyen N, Wilson LC, Barel D, Clayton-Smith J, de Ravel T, Decock C, Delbeke P, Ensenauer R, Ebinger F, Gillessen-Kaesbach G, Hendriks Y, Kimonis V, Laframboise R, Laissue P, Leppig K, Leroy BP, Miller DT, Mowat D, Neumann L, Plomp A, Van Regemorter N, Wieczorek D, Veitia RA, De Paepe A, De Baere E (2008) Identification of 34 novel and 56 known FOXL2 mutations in patients with Blepharophimosis syndrome. Hum Mutat 29:E205–E219PubMedCrossRef

19.

Ni F, Wen Q, Wang B, Zhou S, Wang J, Mu Y, Ma X, Cao Y (2010) Mutation analysis of FOXL2 gene in Chinese patients with premature ovarian failure. Gynecol Endocrinol 26:246–249PubMedCrossRef

20.

Moumné L, Dipietromaria A, Batista F, Kocer A, Fellous M, Pailhoux E, Veitia RA (2008) Differential aggregation and functional impairment induced by polyalanine expansions in FOXL2, a transcription factor involved in cranio-facial and ovarian development. Hum Mol Genet 17:1010–1019PubMedCrossRef

21.

Lamba P, Fortin J, Tran S, Wang Y, Bernard DJ (2009) A novel role for the forkhead transcription factor FOXL2 in activin A-regulated follicle-stimulating hormone β subunit transcription. Mol Endocrinol 23:1001–1013PubMedPubMedCentralCrossRef

22.

Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM (2009) FoxL2 and Smad3 coordinately regulate follistatin gene transcription. J Biol Chem 284:7631–7645PubMedPubMedCentralCrossRef

23.

Schlade-Bartusiak K, Brown L, Lomax B, Bruyère H, Gillan T, Hamilton S, McGillivray B, Eydoux P (2012) BPES with atypical premature ovarian insufficiency, and evidence of mitotic recombination, in a woman with trisomy X and a translocation t(3;11)(q22.3;q14.1). Am J Med Genet A 158A:2322–2327PubMedCrossRef

24.

Siewert AL, Stein Q, Flanagan J, Hansen KA (2008) Blepharophimosis-ptosis-epicanthus inversus syndrome and hypergonadotropic hypogonadism. Fertil Steril 90(2016):2006.e11–2006.e12

25.

Nelson LM (2009) Clinical practice. Primary ovarian insufficiency. N Engl J Med 360:606–614PubMedPubMedCentralCrossRef

26.

Verdin H, De Baere E (2012) FOXL2 impairment in human disease. Horm Res Paediatr 77:2–11PubMedCrossRef

27.

Gersak K, Harris SE, Smale WJ, Shelling AN (2004) A novel 30 bp deletion in the FOXL2 gene in a phenotypically normal woman with primary amenorrhoea: case report. Hum Reprod 19:2767–2770PubMedCrossRef

28.

Roth LW, Alvero R (2014) Pregnancy in a woman with premature ovarian insufficiency associated with blepharophimosis, ptosis, epicanthus inversus syndrome type I. A case report. J Reprod Med 59:87–89PubMed

Titel: Characterization of endocrine features and genotype–phenotypes correlations in blepharophimosis–ptosis–epicanthus inversus syndrome type 1
verfasst von: S. Nuovo
M. Passeri
E. Di Benedetto
M. Calanchini
I. Meldolesi
M. C. Di Giacomo
D. Petruzzi
M. R. Piemontese
L. Zelante
F. Sangiuolo
G. Novelli
A. Fabbri
F. Brancati
Publikationsdatum: 01.02.2016
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 2/2016
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0334-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly

Antonello da Messina: Virgin Annunciate

Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis

Thyroid Hürthle cell tumors: research of potential markers of malignancy

Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine